| Dee Shuler-woodard Ii, | |
|
615 Mount Evans St, Longmont, CO 80501-4635 | |
| (303) 678-0818 | |
| (303) 678-0818 |
| Full Name | Dee Shuler-woodard Ii |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 615 Mount Evans St, Longmont, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194825968 | NPI | - | NPPES |
| 53255879 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 0165901 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dee Shuler-woodard Ii, 615 Mount Evans St, Longmont, CO 80501-4635 Ph: (303) 678-0818 | Dee Shuler-woodard Ii, 615 Mount Evans St, Longmont, CO 80501-4635 Ph: (303) 678-0818 |
News Archive
A UCSF institute aimed at accelerating the pace of translating science into real-life solutions for patients has received $112 million from the National Institutes of Health to expand its work over the next five years.
Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200.
Bayard Advertising Agency, Inc., an integrated branding and communications agency serving B2B and B2C clients in a broad array of industries, announces its selection as Recruitment Advertising Agency of Record by Cancer Treatment Centers of America.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.
› Verified 3 days ago
Scarlet Larkin Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 519 Emery St, Longmont, CO 80501 Phone: 303-702-0091 Fax: 303-702-0108 | |
Amy Hamilton Thrasher, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 611 Korte Way, Longmont, CO 80501 Phone: 303-776-7417 | |
Gretel Lys Bey, M.A. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 163 Donovan Ct, Longmont, CO 80501 Phone: 303-682-2645 | |
Chad Hunter Grossman, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 205 Ken Pratt Blvd Ste 120-1005, Longmont, CO 80501 Phone: 215-262-6937 | |
Mrs. Shannon Leah Turley, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 700 Ken Pratt Blvd Ste 106, Longmont, CO 80501 Phone: 970-231-0745 | |
Beth Legg, M.A, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 820 Main St, Longmont, CO 80501 Phone: 303-702-7806 | |
Amanda Lopez, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 711 Darby Ct Apt 205, Longmont, CO 80501 Phone: 612-770-1709 |